The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Sarcoma and Rare Cancers 2023 | Unmet needs and future directions in the treating rare pancreatic cancers
Dirk Arnold, MD, PhD, Asklepios Tumorzentrum Hamburg AK Altona, Hamburg, Germany, discusses the challenges associated with treating and prognostically defining certain pancreatic cancer because of their heterogenous and rare nature. Dr Arnold also emphasizes the lack of high-grade evidence-based recommendations for such malignancies, as well as the difficulty in determining the best molecular route to treat patients with exocrine versus endocrine tumors. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
